Ziyad A Ayyoub, MD
Physical Medicine and Rehabilitation · Paramount
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 40 years
- Graduated 1986
Offices
2 locations
Hospitals listed: Lac/Rancho Los Amigos National Rehabilitation Ctr · Pih Health Downey Hospital · Saint Francis Medical Center · Whittier Hospital Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Ayyoub’s office at (562) 633-0976 to ask if they take your plan before you enroll.
California Medical Board record
Licence A53397 · Current
Licensed to practise in California · since 1994 · expires 2027-12-31 · Minsk Medical Institute.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Lac/Rancho Los Amigos National Rehabilitation CtrDowney, CAAcute Care Hospital · Government - Local · No emergency departmentPart of Los Angeles County Department of Health Services, which runs 4 hospitalsPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 4.73, Oct 2024 – Sep 2025
- Pih Health Downey HospitalDowney, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of PIH Health, which runs 3 hospitalsPatients rate it 3 of 5 · 73% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.157, Oct 2024 – Sep 2025
- Saint Francis Medical CenterLynwood, CAAcute Care Hospital · Voluntary non-profit - Church · No emergency department · Birthing-friendlyPart of Prime Healthcare Services, which runs 45 hospitals in 14 statesPatients rate it 2 of 5 · 62% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.228, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.055, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0, Oct 2024 – Sep 2025
- Whittier Hospital Medical CenterWhittier, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPatients rate it 2 of 5 · 60% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.265, Oct 2024 – Sep 2025
See every measure and the patient survey for Lac/Rancho Los Amigos National Rehabilitation Ctr
Behind the star rating — Deaths: 0 better, 1 the same, 0 worse of 1 measures. Safety: 0 better, 4 the same, 0 worse of 4 measures. Readmissions: 0 better, 1 the same, 0 worse of 1 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 4.73 | Worse | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.05 (0 to 2.15) · 28 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.92 (0.44 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 33 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.21 (0 to 0.44) · 273 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.05 to 0.49) · 276 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.42 (0.81 to 6.03) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.65 (0 to 3.37) · 55 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.3 (0.58 to 4.03) · 71 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.28 (0 to 17.84) · 67 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.14 (0.84 to 9.44) · 40 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.5 (0 to 1.7) · 203 cases | No different | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.816 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 1.702 | No different | Oct 2024 – Sep 2025 |
What patients said (159 patients answered, 16% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 66% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 56% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 55% |
| Yes, staff "did" give patients information about possible symptoms | 81% |
See every measure and the patient survey for Pih Health Downey Hospital
Behind the star rating — Deaths: 1 better, 5 the same, 0 worse of 6 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 4 the same, 2 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.157 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.28 (0.21 to 2.34) · 403 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.44 to 1.29) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.9 · 35 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.9 · 46 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 178 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.9 · 201 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.1 · 160 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.9 · 2,052 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.41) · 2,633 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.46) · 2,714 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.1 (0.61 to 5.59) · 276 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.66 (0 to 3.39) · 27 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.19 (0.51 to 3.87) · 273 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.89 (0 to 18.8) · 29 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (0.84 to 9.46) · 25 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.72 (0.21 to 3.24) · 63 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.29 (0 to 1.22) · 2,012 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.198 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.3 · 124 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 23.1 · 614 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 3.7 · 229 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 16.5 · 234 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.8 · 495 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 86 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.6 (9.3 to 16.8) · 432 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 156 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,108 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 77% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 80% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 81% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 73% |
| Staff "always" explained possible side effects | 39% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Saint Francis Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 3 better, 3 the same, 0 worse of 6 measures. Readmissions: 1 better, 4 the same, 0 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.228 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.055 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.99 (0 to 2.05) · 378 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.82 (0.42 to 1.21) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 171.25 (124.53 to 217.98) · 45 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.9 · 37 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.3 · 65 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.5 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.3 · 218 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.6 · 1,566 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,230 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 3,280 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.98 (0.54 to 5.42) · 356 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.67 (0 to 3.4) · 34 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.13 (0.47 to 3.79) · 343 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.03 (0 to 19.03) · 39 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.11 (0.82 to 9.39) · 35 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.27) · 38 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.19 (0 to 0.92) · 2,725 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.436 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.183 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 195 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.2 · 370 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -36.8 · 57 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -26.7 · 196 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -11.8 · 215 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.1 · 364 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.4 · 92 cases | None | Jul 2023 – Jun 2025 |
What patients said (575 patients answered, 34% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 77% |
| Nurses "always" communicated well | 70% |
| Doctors "always" communicated well | 70% |
| Staff "always" explained | 52% |
| Yes, staff "did" give patients this information | 81% |
| Yes, staff "did" give patients information about help after discharge | 79% |
| Doctors "always" explained things so they could understand | 64% |
| Doctors "always" listened carefully | 68% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 65% |
| Staff "always" explained new medications | 66% |
| Nurses "always" explained things so they could understand | 65% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 79% |
| "Always" quiet at night | 51% |
| "YES", patients would definitely recommend the hospital | 62% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
See every measure and the patient survey for Whittier Hospital Medical Center
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 0 better, 5 the same, 0 worse of 5 measures. Readmissions: 0 better, 4 the same, 1 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.265 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.03 (0 to 2.1) · 342 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.44 to 1.33) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.7 · 40 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.2 · 175 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 40 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.9 · 903 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.42) · 1,603 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.04 to 0.47) · 1,665 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.29 (0.73 to 5.86) · 153 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.67 (0 to 3.4) · 33 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.27 (0.56 to 3.98) · 152 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.99 (0 to 18.96) · 36 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.22 (0.88 to 9.55) · 32 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.73 (0.21 to 3.25) · 55 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.34 (0 to 1.32) · 1,393 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 63 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.575 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 191 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 2 · 101 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 15.3 · 199 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.7 · 319 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 71 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 96 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.7 to 17.8) · 98 cases | No different | Jan 2022 – Dec 2024 |
What patients said (540 patients answered, 15% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 2 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 73% |
| Staff "always" explained | 64% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 67% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 79% |
| Patients who gave a rating of "9" or "10" (high) | 62% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 51% |
| "YES", patients would definitely recommend the hospital | 60% |
| Staff "always" explained possible side effects | 53% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
Original Medicare doctor bills
$483,015
Medicare paid this office $483,015 for 362 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 319 | $396,953 | $65 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 279 | $41,339 | $142 |
| Return visit (30+ min) | 36 | $18,111 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 47 | $8,703 | $98 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | 11 | $4,472 | $154 |
See all 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 319 | $396,953 | $65 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 279 | $41,339 | $142 |
| Return visit (30+ min) | 36 | $18,111 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 47 | $8,703 | $98 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | 11 | $4,472 | $154 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 32 | $3,375 | $41 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $1,823 | $107 |
| Electrical stimulation for guidance with injection of chemical for paralysis of nerve muscle | 12 | $1,792 | $64 |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | – | – | – | – | – | 29 |
| Injection of trigger points, 3 or more muscles | 23 | – | – | – | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
362 Original Medicare patients in 2024. Average age 72 · Under 65 21% · 85 and older 18% · Women 53% · Also on Medicaid 80% · Health risk score 4.39. Sicker patients than 9 in 10 peers; the typical physical medicine and rehabilitation clinician is at 1.53.
Conditions among them: High blood pressure 75% · Diabetes 75% · Heart failure 72% · Chronic kidney disease 68% · Depression 57% · Coronary heart disease 54% · COPD 49% · Atrial fibrillation 45% · Dementia 44% · Stroke 40% · Cancer 14%.
The office billed $2,903,915, Medicare allowed $612,454 and paid $483,015; for 6,941 services of 21 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 362 | 6,941 | 72 | 4.39 | $2,903,915 | $483,015 |
| 2023 | 233 | 4,312 | 70 | 3.87 | $1,808,246 | $304,006 |
| 2022 | 148 | 2,567 | 69 | 3.77 | $1,035,087 | $173,370 |
| 2021 | 131 | 2,199 | 67 | 3.75 | $863,917 | $152,368 |
| 2020 | 124 | 2,311 | 67 | 4.42 | $909,449 | $156,611 |
| 2019 | 133 | 2,194 | 66 | 4.34 | $420,113 | $125,534 |
| 2018 | 169 | 2,903 | 65 | 4.71 | $333,060 | $166,865 |
| 2017 | 269 | 3,858 | 68 | 4.81 | $422,772 | $234,579 |
| 2016 | 294 | 3,891 | 68 | 4.66 | $420,424 | $232,518 |
| 2015 | 429 | 4,434 | 67 | 3.99 | $522,850 | $289,346 |
| 2014 | 448 | 4,670 | 64 | 3.79 | $515,266 | $265,345 |
| 2013 | 566 | 5,473 | 66 | 3.58 | $620,917 | $323,231 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 187 | $257,589 | $66 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 152 | $21,676 | $141 |
| Return visit (30+ min) | 38 | $16,220 | $100 |
2022: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 95 | $130,928 | $60 |
| Return visit (30+ min) | 41 | $20,276 | $102 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 85 | $13,948 | $162 |
2021: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 86 | $109,935 | $61 |
| Return visit (30+ min) | 41 | $22,557 | $108 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 70 | $11,848 | $165 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $1,414 | $88 |
2020: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 75 | $116,232 | $62 |
| Return visit (30+ min) | 41 | $12,097 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 49 | $10,992 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 59 | $10,333 | $175 |
2019: 10 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 58 | $54,311 | $61 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 37 | $25,334 | $33 |
| Return visit (30+ min) | 49 | $14,933 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 39 | $6,908 | $85 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 37 | $6,227 | $164 |
| Long return visit (40+ min) | 28 | $5,415 | $108 |
| New patient visit (60+ min) | 21 | $2,965 | $141 |
| Injection of trigger points, 3 or more muscles | 12 | $1,044 | $45 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 15 | $43 | None |
| Injection, lidocaine hcl for intravenous infusion, 10 mg | 15 | $1 | None |
2018: 10 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 83 | $70,724 | $60 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 58 | $33,141 | $32 |
| Return visit (30+ min) | 55 | $17,601 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 66 | $14,228 | $85 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 64 | $10,709 | $167 |
| Long return visit (40+ min) | 35 | $7,288 | $114 |
| New patient visit (60+ min) | 19 | $3,232 | $170 |
| Injection of trigger points, 3 or more muscles | 12 | $1,337 | $48 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 15 | $46 | None |
| Injection, lidocaine hcl for intravenous infusion, 10 mg | 12 | $1 | None |
2017: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 178 | $98,981 | $59 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 98 | $35,039 | $32 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 114 | $30,068 | $85 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 150 | $24,703 | $163 |
| Return visit (30+ min) | 48 | $16,409 | $83 |
| Long return visit (40+ min) | 51 | $16,132 | $111 |
| New patient visit (60+ min) | 18 | $2,914 | $162 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,789 | $112 |
| Injection of trigger points, 3 or more muscles | 19 | $1,703 | $49 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 23 | $81 | None |
| Injection, lidocaine hcl for intravenous infusion, 10 mg | 17 | $1 | None |
2016: 10 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 183 | $83,518 | $60 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 156 | $48,348 | $33 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 119 | $30,680 | $87 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 127 | $22,128 | $169 |
| Return visit (30+ min) | 57 | $17,131 | $86 |
| Long return visit (40+ min) | 45 | $12,556 | $118 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 51 | $5,925 | $114 |
| New patient visit (60+ min) | 12 | $1,941 | $162 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 17 | $42 | None |
| Injection, lidocaine hcl for intravenous infusion, 10 mg | 12 | $0 | None |
2015: 14 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 270 | $109,077 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 168 | $47,140 | $87 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 227 | $39,295 | $170 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 231 | $37,919 | $32 |
| Long return visit (40+ min) | 51 | $19,468 | $117 |
| Return visit (30+ min) | 58 | $18,079 | $87 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 50 | $5,556 | $111 |
| New patient visit (60+ min) | 19 | $3,332 | $175 |
| Injection of trigger points, 3 or more muscles | 12 | $1,605 | $50 |
| Aspiration and/or injection of fluid from large joint | 12 | $1,055 | $44 |
| Short return visit | 15 | $253 | $17 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 20 | $160 | $7 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 23 | $92 | None |
| Injection, lidocaine hcl for intravenous infusion, 10 mg | 14 | $1 | None |
2014: 14 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 264 | $92,764 | $59 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 232 | $63,256 | $33 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 187 | $32,970 | $169 |
| Return visit (30+ min) | 68 | $21,200 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 100 | $17,453 | $86 |
| Long return visit (40+ min) | 54 | $15,351 | $119 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 51 | $5,899 | $113 |
| New patient visit (60+ min) | 24 | $4,196 | $175 |
| Extended inpatient or observation hospital service, first hour | 16 | $1,238 | $77 |
| Injection of trigger points, 3 or more muscles | 15 | $1,218 | $38 |
| Aspiration and/or injection of fluid from large joint | 13 | $979 | $47 |
| Short return visit | 37 | $928 | $19 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 30 | $310 | $7 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 25 | $76 | None |
2013: 13 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 352 | $145,025 | $58 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 286 | $52,940 | $31 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 208 | $33,870 | $162 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 141 | $27,682 | $83 |
| Return visit (30+ min) | 64 | $19,079 | $84 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 124 | $13,570 | $109 |
| Long return visit (40+ min) | 48 | $13,369 | $116 |
| New patient visit (60+ min) | 24 | $3,814 | $159 |
| Initial nursing facility care with straightforward or low level of medical decision making, per day at least 25 minutes | 28 | $2,172 | $78 |
| Initial nursing facility care with moderate level of medical decision making, per day at least 35 minutes | 17 | $1,799 | $106 |
| Short return visit | 49 | $1,557 | $19 |
| Electrical stimulation for guidance with injection of chemical for paralysis of nerve muscle | 12 | $1,395 | $63 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 12 | $23 | None |
Medicaid work
$33,196 in 2024
Medicaid paid $33,196 for 1,939 billed services this clinician did in 2024, up to 26 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 1,869 | $32,114 |
| Return visit (30+ min) | 53 | $690 |
| 1ST HOSP IP/OBS HIGH 75 | 17 | $392 |
| 2024 | 1,939 | 3 | 26 | $33,196 |
| 2023 | 1,932 | 2 | 21 | $51,652 |
| 2022 | 31 | 1 | 15 | $1,174 |
| 2020 | 12 | 1 | 12 | $81 |
| 2019 | 34 | 1 | 17 | $114 |
| 2018 | 203 | 5 | 16 | $3,063 |
See the largest Medicaid services in earlier years
2023
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 1,874 | $50,226 |
| Return visit (30+ min) | 58 | $1,426 |
2022
| Return visit (30+ min) | 31 | $1,174 |
2020
| Short return visit (20+ min) | 12 | $81 |
2019
| Short return visit (20+ min) | 34 | $114 |
2018
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 22 | $1,398 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 110 | $983 |
| Return visit (30+ min) | 40 | $546 |
| Short return visit (20+ min) | 15 | $137 |
| Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 16 | $0 |
Drugs they prescribed that Part D paid
$186,335
Pharmacies billed $186,335 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 45% of their Part D prescriptions (182 of 408) in 2024. Above the middle of the specialty; the typical physical medicine and rehabilitation clinician is at 12%.
330 generic and 78 brand-name prescriptions · $186,335 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Botox | 73 | $181,411 | $2,485 |
| Hydrocodone-Acetaminophen | 123 | $1,362 | $11 |
| Oxycodone-Acetaminophen | 36 | $798 | $22 |
| Gabapentin | 50 | $445 | $9 |
| Oxycodone | 13 | $352 | $27 |
See all 7 drugs
| Botox | 73 | $181,411 | $2,485 |
| Hydrocodone-Acetaminophen | 123 | $1,362 | $11 |
| Oxycodone-Acetaminophen | 36 | $798 | $22 |
| Gabapentin | 50 | $445 | $9 |
| Oxycodone | 13 | $352 | $27 |
| Ibuprofen | 22 | $68 | $3 |
| Baclofen | 19 | $56 | $3 |
Year by year
| 2024 | 408 | 62 | 45% (182) | 19% | $186,335 |
| 2023 | 357 | 59 | 47% (168) | 23% | $240,913 |
| 2022 | 319 | 50 | 57% (181) | 20% | $171,772 |
| 2021 | 378 | 46 | 59% (222) | 16% | $130,185 |
| 2020 | 382 | 70 | 52% (199) | 9% | $80,847 |
| 2019 | 401 | 75 | 41% (163) | 16% | $112,988 |
| 2018 | 483 | 79 | 38% (182) | 14% | $129,770 |
| 2017 | 535 | 76 | 40% (214) | 19% | $143,585 |
| 2016 | 548 | 82 | 40% (219) | 19% | $136,563 |
| 2015 | 679 | 76 | 42% (286) | 23% | $138,251 |
| 2014 | 785 | 88 | 39% (303) | 25% | $186,391 |
| 2013 | 701 | 82 | 40% (283) | 37% | $168,057 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Botox | 83 | $234,071 | $2,820 |
| Hydrocodone-Acetaminophen | 111 | $1,950 | $18 |
| Oxycodone-Acetaminophen | 26 | $820 | $32 |
| Gabapentin | 34 | $781 | $23 |
| Baclofen | 12 | $469 | $39 |
| Oxycodone | 12 | $266 | $22 |
| Tramadol | 19 | $242 | $13 |
2022: 7 drugs
| Botox | 63 | $167,030 | $2,651 |
| Hydrocodone-Acetaminophen | 127 | $1,841 | $14 |
| Oxycodone-Acetaminophen | 25 | $657 | $26 |
| Gabapentin | 26 | $479 | $18 |
| Nortriptyline | 11 | $127 | $12 |
| Ibuprofen | 11 | $109 | $10 |
| Tramadol | 13 | $61 | $5 |
2021: 8 drugs
| Botox | 52 | $123,086 | $2,367 |
| Hydrocodone-Acetaminophen | 136 | $1,958 | $14 |
| Oxycodone-Acetaminophen | 23 | $641 | $28 |
| Baclofen | 15 | $588 | $39 |
| Gabapentin | 26 | $448 | $17 |
| Oxycodone | 11 | $348 | $32 |
| Ibuprofen | 29 | $169 | $6 |
| Tramadol | 23 | $65 | $3 |
2020: 10 drugs
| Botox | 31 | $62,989 | $2,032 |
| Hydrocodone-Acetaminophen | 124 | $1,801 | $15 |
| Oxycodone-Acetaminophen | 30 | $926 | $31 |
| Gabapentin | 49 | $812 | $17 |
| Baclofen | 24 | $728 | $30 |
| Duloxetine | 12 | $668 | $56 |
| Oxycodone | 11 | $249 | $23 |
| Ibuprofen | 31 | $203 | $7 |
| Naproxen | 15 | $96 | $6 |
| Tramadol | 25 | $90 | $4 |
2019: 10 drugs
| Botox | 39 | $86,449 | $2,217 |
| Hydrocodone-Acetaminophen | 92 | $1,057 | $11 |
| Duloxetine | 18 | $1,052 | $58 |
| Baclofen | 55 | $1,019 | $19 |
| Gabapentin | 49 | $773 | $16 |
| Oxycodone-Acetaminophen | 20 | $588 | $29 |
| Tramadol | 23 | $126 | $5 |
| Acetaminophen-Codeine | 12 | $122 | $10 |
| Ibuprofen | 18 | $119 | $7 |
| Naproxen | 15 | $91 | $6 |
2018: 11 drugs
| Botox | 50 | $108,372 | $2,167 |
| Gabapentin | 91 | $1,447 | $16 |
| Duloxetine | 17 | $1,330 | $78 |
| Baclofen | 65 | $1,269 | $20 |
| Hydrocodone-Acetaminophen | 102 | $1,196 | $12 |
| Oxycodone-Acetaminophen | 30 | $771 | $26 |
| Morphine Sulfate Er | 13 | $357 | $27 |
| Ibuprofen | 22 | $190 | $9 |
| Tramadol | 17 | $153 | $9 |
| Acetaminophen-Codeine | 11 | $101 | $9 |
| Naproxen | 14 | $94 | $7 |
2017: 14 drugs
| Botox | 57 | $112,125 | $1,967 |
| Lyrica | 26 | $14,877 | $572 |
| Dantrolene | 11 | $2,139 | $194 |
| Gabapentin | 93 | $1,650 | $18 |
| Hydrocodone-Acetaminophen | 109 | $1,086 | $10 |
| Baclofen | 51 | $870 | $17 |
| Oxycodone-Acetaminophen | 29 | $699 | $24 |
| Oxycodone | 20 | $497 | $25 |
| Morphine Sulfate Er | 15 | $463 | $31 |
| Duloxetine | 14 | $388 | $28 |
| Tramadol | 18 | $134 | $7 |
| Acetaminophen-Codeine | 11 | $105 | $10 |
| Ibuprofen | 13 | $100 | $8 |
| Trazodone | 13 | $28 | $2 |
2016: 15 drugs
| Botox | 49 | $103,581 | $2,114 |
| Lyrica | 30 | $14,901 | $497 |
| Oxycontin | 12 | $2,739 | $228 |
| Dantrolene | 15 | $2,448 | $163 |
| Gabapentin | 106 | $2,264 | $21 |
| Hydrocodone-Acetaminophen | 96 | $2,068 | $22 |
| Morphine Sulfate Er | 18 | $969 | $54 |
| Baclofen | 28 | $811 | $29 |
| Oxycodone-Acetaminophen | 19 | $760 | $40 |
| Oxycodone | 20 | $502 | $25 |
| Acetaminophen-Codeine | 16 | $256 | $16 |
| Ibuprofen | 31 | $237 | $8 |
| Naproxen | 18 | $127 | $7 |
| Tramadol | 25 | $121 | $5 |
| Trazodone | 16 | $55 | $3 |
2015: 17 drugs
| Botox | 34 | $69,198 | $2,035 |
| Lyrica | 36 | $17,411 | $484 |
| Oxycontin | 30 | $8,938 | $298 |
| Lidocaine | 14 | $5,321 | $380 |
| Voltaren | 32 | $3,689 | $115 |
| Duloxetine | 24 | $2,776 | $116 |
| Hydrocodone-Acetaminophen | 110 | $2,182 | $20 |
| Morphine Sulfate Er | 38 | $2,049 | $54 |
| Gabapentin | 93 | $1,884 | $20 |
| Oxycodone-Acetaminophen | 25 | $1,818 | $73 |
| Dantrolene | 15 | $1,709 | $114 |
| Oxycodone | 20 | $852 | $43 |
| Baclofen | 23 | $843 | $37 |
| Tramadol | 34 | $208 | $6 |
| Ibuprofen | 22 | $200 | $9 |
| Naproxen | 11 | $126 | $11 |
| Trazodone | 22 | $93 | $4 |
2014: 23 drugs
| Botox | 30 | $63,397 | $2,113 |
| Lidocaine | 84 | $32,496 | $387 |
| Lyrica | 62 | $21,300 | $344 |
| Xeomin | 13 | $20,154 | $1,550 |
| Lidoderm | 28 | $9,887 | $353 |
| Oxycontin | 23 | $4,881 | $212 |
| Celebrex | 12 | $4,011 | $334 |
| Duloxetine | 23 | $3,577 | $156 |
| Morphine Sulfate Er | 51 | $3,131 | $61 |
| Gabapentin | 89 | $2,223 | $25 |
| Hydrocodone-Acetaminophen | 115 | $1,989 | $17 |
| Oxycodone-Acetaminophen | 31 | $1,875 | $60 |
| Dantrolene | 11 | $1,519 | $138 |
| Oxycodone | 21 | $1,167 | $56 |
| Voltaren | 11 | $1,086 | $99 |
| Baclofen | 18 | $1,033 | $57 |
| Tramadol | 37 | $321 | $9 |
| Tizanidine | 12 | $298 | $25 |
| Carisoprodol | 15 | $266 | $18 |
| Acetaminophen-Codeine | 13 | $198 | $15 |
| Naproxen | 15 | $176 | $12 |
| Ibuprofen | 14 | $133 | $9 |
| Trazodone | 13 | $63 | $5 |
2013: 16 drugs
| Botox | 36 | $83,758 | $2,327 |
| Lyrica | 71 | $21,906 | $309 |
| Lidoderm | 44 | $16,553 | $376 |
| Oxycontin | 40 | $10,926 | $273 |
| Cymbalta | 25 | $5,326 | $213 |
| Gabapentin | 108 | $5,154 | $48 |
| Voltaren | 19 | $2,025 | $107 |
| Hydrocodone-Acetaminophen | 106 | $1,776 | $17 |
| Morphine Sulfate Er | 27 | $1,378 | $51 |
| Oxycodone Hcl-Acetaminophen | 22 | $961 | $44 |
| Oxycodone | 18 | $742 | $41 |
| Acetaminophen-Codeine | 16 | $228 | $14 |
| Tramadol | 21 | $221 | $11 |
| Ibuprofen | 27 | $195 | $7 |
| Carisoprodol | 18 | $144 | $8 |
| Naproxen | 12 | $85 | $7 |
Money from drug and device companies
$22,399 in 2025
| 2025 | 3 | 22 | $20,942 | $22,399 |
| 2024 | 5 | 65 | $33,225 | $37,561 |
| 2023 | 6 | 68 | $38,940 | $47,457 |
| 2022 | 5 | 48 | $43,256 | $47,016 |
| 2021 | 4 | 47 | $60,667 | $62,466 |
| 2020 | 5 | 34 | $27,700 | $28,366 |
| 2019 | 7 | 141 | $62,553 | $76,365 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Botox | $22,127 | 19 payments
|
| Merz Pharmaceuticals | Xeomin | $149 | 1 payment
|
| Lundbeck | Vyepti | $122 | 2 payments
|
See all 22 published payments
| Abbvie | Consulting · 2025-12-18 | Botox | $1,400 |
| Abbvie | Paid to speak or teach · 2025-12-11 | Botox | $5,600 |
| Abbvie | Paid to speak or teach · 2025-09-25 | Botox | $1,050 |
| Lundbeck | Meals · 2025-09-10 | Vyepti | $60 |
| Lundbeck | Meals · 2025-09-10 | Vyepti | $63 |
| Abbvie | Consulting · 2025-08-21 | Botox | $467 |
| Abbvie | Consulting · 2025-08-21 | Botox | $3,850 |
| Abbvie | Consulting · 2025-08-21 | Botox | $1,050 |
| Merz Pharmaceuticals | Meals · 2025-07-17 | Xeomin | $149 |
| Abbvie | Meals · 2025-06-28 | Botox | $57 |
| Abbvie | Meals · 2025-06-28 | Botox | $67 |
| Abbvie | Meals · 2025-06-28 | Botox | $24 |
| Abbvie | Meals · 2025-06-28 | Botox | $112 |
| Abbvie | Travel · 2025-06-27 | Botox | $300 |
| Abbvie | Travel · 2025-06-27 | Botox | $467 |
| Abbvie | Meals · 2025-06-24 | Botox | $21 |
| Abbvie | Paid to speak or teach · 2025-05-16 | Botox | $700 |
| Abbvie | Paid to speak or teach · 2025-05-12 | Botox | $700 |
| Abbvie | Paid to speak or teach · 2025-04-07 | Botox | $5,600 |
| Abbvie | Meals · 2025-03-20 | Botox | $34 |
| Abbvie | Meals · 2025-01-21 | Botox | $103 |
| Abbvie | Consulting · 2025-01-07 | Botox | $525 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $37,561
| Abbvie | Botox | $29,071 | 37 payments
|
| Ipsen Biopharmaceuticals | Dysport | $6,509 | 7 payments
|
| Pacira Pharmaceuticals | Zilretta | $1,299 | 9 payments
|
| Merz Pharmaceuticals | Xeomin | $420 | 10 payments
|
| Revance Therapeutics | Daxi | $263 | 2 payments
|
2023: $47,457
| Ipsen Biopharmaceuticals | Dysport | $24,410 | 19 payments
|
| AbbVie | Botox | $20,576 | 28 payments
|
| Pacira Pharmaceuticals | Iovera | $885 | 7 payments
|
| MDD US Operations | Myobloc | $880 | 1 payment
|
| Merz Pharmaceuticals | Xeomin | $669 | 11 payments
|
| Novo Nordisk | None | $38 | 2 payments
|
2022: $47,016
| Abbvie | Botox | $21,010 | 21 payments
|
| Allergan | Botox | $15,463 | 10 payments
|
| Ipsen Biopharmaceuticals | Dysport | $6,267 | 8 payments
|
| Merz Pharmaceuticals | Xeomin | $3,253 | 7 payments
|
| Ipsen Pharma SAS | Dysport | $1,022 | 2 payments
|
2021: $62,466
| Allergan | Botox | $41,457 | 30 payments
|
| Ipsen Biopharmaceuticals | Dysport | $15,366 | 11 payments
|
| Ipsen Biopharm | Dysport | $4,380 | 1 payment
|
| Merz Pharmaceuticals | Xeomin | $1,263 | 5 payments
|
2020: $28,366
| Allergan | Botox | $9,832 | 16 payments
|
| Ipsen Biopharmaceuticals | Dysport | $9,707 | 4 payments
|
| Ipsen Innovation | Dysport | $5,735 | 5 payments
|
| Merz North America | Xeomin | $2,592 | 8 payments
|
| US WorldMeds | None | $500 | 1 payment
|
2019: $76,365
| Merz North America | Xeomin | $27,652 | 34 payments
|
| Allergan | Botox | $25,420 | 33 payments
|
| US WorldMeds | Myobloc | $15,415 | 50 payments
|
| Ipsen Biopharmaceuticals | Dysport | $6,244 | 10 payments
|
| Ipsen Pharma SAS | Dysport | $892 | 3 payments
|
| Nevro | Senza Spinal Cord Stimulation System | $721 | 10 payments
|
| Medtronic USA | Synchromed | $21 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Ipsen Pharma SAS · A Multicentre, Interventional, Post-Marketing, Randomised, Double-Blind, Crossover Study To Evaluate the Clinical Safety and Efficacy of Abobotulinumtoxina (Dysport) in Comparison With Onabotulinumtoxina (Botox) When Treating Adults With Upper Limb Spasticity · 2022 | Their institution | $348,515 |
| Merz Pharmaceuticals, LLC · Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Investigate the Efficacy and Safety of Nt 201 in the Treatment of Lower Limb Spasticity Caused By Stroke Or Traumatic Brain Injury in Adult Subjects, Followed By An Open Label Extension With Or Without Combined Upper Limb Treatment · 2025 | Their institution | $245,916 |
| MDD US Operations, LLC · A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of Myobloc in the Treatment of Adult Upper Limb Spasticity Followed By An Open-Label Extension, Multiple-Treatment Safety Study of Myobloc · 2023 | Their institution | $234,948 |
| Ipsen Pharma SAS · A Multicentre, Interventional, Post-Marketing, Randomised, Double-Blind, Crossover Study To Evaluate the Clinical Safety and Efficacy of Abobotulinumtoxina (Dysport) in Comparison With Onabotulinumtoxina (Botox) When Treating Adults With Upper Limb Spasticity · 2023 | Their institution | $102,510 |
| MDD US Operations, LLC · A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of Myobloc in the Treatment of Adult Lower Limb Spasticity Followed By An Open-Label Extension, Multiple-Treatment Safety Study of Myobloc · 2023 | Their institution | $93,466 |
| Merz Pharmaceuticals, LLC · Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Investigate the Efficacy and Safety of Nt 201 in the Treatment of Lower Limb Spasticity Caused By Stroke Or Traumatic Brain Injury in Adult Subjects, Followed By An Open Label Extension With Or Without Combined Upper Limb Treatment · 2024 | Their institution | $75,763 |
| MDD US Operations, LLC · A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of Myobloc in the Treatment of Adult Upper Limb Spasticity Followed By An Open-Label Extension, Multiple-Treatment Safety Study of Myobloc · 2022 | Their institution | $74,776 |
| Ipsen Pharma SAS · International, Multicentre, Observational, Prospective, Longitudinal Study To Assess the Effectiveness of Abobont-A Injections for Adult Lower Limb Spasticity in A Real Life Cohort (Abolish) · 2021 | Their institution | $48,050 |
| MDD US Operations, LLC · A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of Myobloc in the Treatment of Adult Lower Limb Spasticity Followed By An Open-Label Extension, Multiple-Treatment Safety Study of Myobloc · 2021 | Their institution | $46,331 |
| Pacira Pharmaceuticals Incorporated · A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of Iovera®° System in Subjects With Upper Extremity Spasticity · 2025 | Their institution | $34,132 |
| ABBVIE INC. · Study of Intramuscular Injections of Abbv-950 To Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity · 2024 | Their institution | $26,826 |
| Ipsen Innovation · Arma · 2023 | Their institution | $23,594 |
| Ipsen Pharma SAS · International, Multicentre, Observational, Prospective, Longitudinal Study To Assess the Effectiveness of Abobont-A Injections for Adult Lower Limb Spasticity in A Real Life Cohort (Abolish) · 2022 | Their institution | $19,525 |
| ABBVIE INC. · M23-499 Ph 2 Spasticity · 2024 | Their institution | $19,517 |
| Ipsen Innovation · An Integrated Phase I/II, Multicentre, Double-Blind, Randomised, Dysport and Placebo-Controlled, Dose Escalation and Dose-Finding Study To Evaluate the Safety and Efficacy of Ipn10200 in the Treatment of Adult Upper Limb Spasticity. · 2025 | Their institution | $8,005 |
| Ipsen Pharma SAS · International, Multicentre, Observational, Prospective, Longitudinal Study To Assess the Effectiveness of Abobont-A Injections for Adult Lower Limb Spasticity in A Real Life Cohort Abolish · 2020 | Their institution | $7,100 |
| Ipsen Pharma SAS · A Multicentre, Interventional, Post-Marketing, Randomised, Double-Blind, Crossover Study To Evaluate the Clinical Safety and Efficacy of Abobotulinumtoxina (Dysport) in Comparison With Onabotulinumtoxina (Botox) When Treating Adults With Upper Limb Spasticity · 2024 | Their institution | $6,255 |
| Supernus Pharmaceuticals, Inc. · A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of Myobloc in the Treatment of Adult Upper Limb Spasticity Followed By An Open-Label Extension, Multiple-Treatment Safety Study of Myobloc · 2024 | Their institution | $5,400 |
| ABBVIE INC. · M23-499 - Study of Intramuscular Injections of Abbv-950 To Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity · 2025 | Their institution | $5,250 |
| Supernus Pharmaceuticals, Inc. · A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of Myobloc in the Treatment of Adult Lower Limb Spasticity Followed By An Open-Label Extension, Multiple-Treatment Safety Study of Myobloc Spasticity · 2024 | Their institution | $4,200 |
| Merz Pharmaceuticals, LLC · Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Investigate the Efficacy and Safety of Nt 201 in the Treatment of Lower Limb Spasticity Caused By Stroke Or Traumatic Brain Injury in Adult Subjects, Followed By An Open Label Extension With Or Without Combined Upper Limb Treatment · 2024 | This clinician | $1,496 |
| ABBVIE INC. · Study of Intramuscular Injections of Abbv-950 To Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity · 2023 | Their institution | $349 |
Professional record
- NPI
- 1356451579
- Licence
- CA A53397California A53397: Current · expires 2027-12-31
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 208100000X (208100000X); Federal specialty code 2081P0004X (2081P0004X); Federal specialty code 2081P2900X (2081P2900X); General practice (208D00000X)
- Mailing address
- Po Box 90936, City of Industry, CA, 91715
- NPI first listed
- 2006-08-30
- NPI last updated
- 2023-04-12
- NPI record certified
- 2023-04-12
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 7601 Imperial Hwy, Downey, CA, 90242